Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations
NCT ID: NCT01636154
Last Updated: 2016-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2012-01-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Research of Effectiveness and Safety of Herbal Medicine Strategy for Chronic Low Back Pain
NCT07058376
An Examination of Blinding for Chinese Herbal Oral Liquid and Matched Placebo
NCT05483595
Clinical Trials of Two Helichrysum Infusions in Adults
NCT04866628
Efficacy and Safety of Chinese Herbal HuoXue LiShui Formula for Chronic Subdural Hematoma
NCT06427980
Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules
NCT06166121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The basic treatment
Comply to the Chinese guidelines of acute ischemic stroke in 2010
No interventions assigned to this group
Clearing heat
Treat with KDZ injection on the basis of the basic treatment
Ixeris of sonchifolia Hance
KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Promoting blood circulation
Treat with Xueshuantong injection on the basis of the basic treatment
Panax notoginseng saponins
Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Clearing heat & Promoting blood circulation
Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ixeris of sonchifolia Hance
KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Panax notoginseng saponins
Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with fire-heat syndrome
* Stoke onset within 48 hours
* NIHSS scores range from 5 points to 25 points
* Age from forty to seventy-five,gender not limited
* Informed and signed the consent
Exclusion Criteria
* Patients suitable for thrombolytic therapy(rt-PA, urokinase)
* Patients have received thrombolytic therapy
* Patients with serious diseases of heart,lungs,liver,kidneys
* Patients with bleeding or bleeding tendency recently
* Pregnant or lactating women
* Pre-existing neurological or psychiatric diseases that could confound the study results
* Patients be allergic to alcohol,Ixeris of sonchifolia Hance components (KDZ injection) or Panax notoginseng saponins components (Xueshuantong injection)
* Patients have participated in other clinical trials within 3 months
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University of Traditional Chinese Medicine
OTHER
Huairou Hospital of Traditional Chinese Medicine
OTHER
Yunling Zhang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yunling Zhang
President of of Dongfang Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yunling Zhang, PhD,MD
Role: STUDY_CHAIR
Dongfang Hospital Beijing University of Chinese Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Neurology,Dongfang Hospital,Beijing University of Chinese Medicine
Beijing, Beijing Municipality, China
Department of Neurology,Huairou Hospital of Traditional Chinese Medicine
Beijing, Beijing Municipality, China
Department of Neurology,Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liu X, Jin X, Chen B, Liu X, Liang X, Fang X, Wu H, Fu X, Zheng H, Ding X, Duan N, Zhang Y. Effects of Kudiezi Injection on Serum Inflammatory Biomarkers in Patients with Acute Cerebral Infarction. Dis Markers. 2018 Sep 2;2018:7936736. doi: 10.1155/2018/7936736. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BUCMDFH9634
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.